Inhibitex Receives Fast Track Designation for INX-189 for the Treatment of Chronic Hepatitis C Infections

[Guest guest]

Infectious Disease

Inhibitex Receives Fast Track Designation for INX-189 for the Treatment of

Chronic Hepatitis C Infections

From the PharmaLive.com News Archive - Feb. 11, 2011

Inhibitex today reported that the FDA has designated the investigation of

INX-08189 , a potent guanosine nucleotide polymerase inhibitor for the treatment

of chronic hepatitis C viral infection, as a Fast Track development program.

Under the FDA Modernization Act of 1997, The characteristics of INX-189 that

contributed to it being granted Fast Track status include a high genetic barrier

to resistance, its pan-genotypic activity, and once-daily oral dosing.

[Guest guest]

Infectious Disease

Inhibitex Receives Fast Track Designation for INX-189 for the Treatment of

Chronic Hepatitis C Infections

From the PharmaLive.com News Archive - Feb. 11, 2011

Inhibitex today reported that the FDA has designated the investigation of

INX-08189 , a potent guanosine nucleotide polymerase inhibitor for the treatment

of chronic hepatitis C viral infection, as a Fast Track development program.

Under the FDA Modernization Act of 1997, The characteristics of INX-189 that

contributed to it being granted Fast Track status include a high genetic barrier

to resistance, its pan-genotypic activity, and once-daily oral dosing.